phe (Total 178 Patents Found)

Phe (178 Patents Found)
The components in this application utilize advanced ceramics, which are homogeneous rather than crystalline. This feature allows strong, fine detail parts of great definition, that remain stable and have extraordinary wear resistant characteristics. The Porcupine Pin is a solid-bodied extrusion from a surface through a...
Combinations of cyclo-(N-methyl-Ala-Tyr-D-Trp-Lys-Val-Phe) and a NSAID have been found to exhibit much lower gastric lesions or ulcers than normally associated with NSAIDs and are thereby clinically useful in long-term therapy for patients suffering from chronic rheumatoid arthritis or osteoarthritis....
Disclosed are DNA sequences bonding deletion, substitution and/or addition analogs of the E. coli enzyme, chorismate mutase/prephenate dehydratase (CMPD). Preferred expression products include [des-Gln 307 , des-Ala 308 , des-Gly 309 , des-Ala 310 ]CMPD; [Leu 306 ]CMPD; [des-Thr 304 , Lys 305 , des-Gln 306 ]CMPD; an...
The present invention provides an antimicrobial composition containing cis -cyclo(L-Leu-L-Pro) as an active ingredient and having specific antimicrobial activity against the genus Streptococcus or bacteria of the genus Shigella , a pesticide composition, and a method for producing an antimicrobial agent. The presen...
Novel unnatural dipeptoids of α-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, colorectal tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents...
La présente invention concerne des méthodes pour traiter une malignité lymphoproliférative chez un patient ayant besoin d'un tel traitement, lesquelles méthodes consistent à administrer au patient une quantité efficace d'un composé A, tel que décrit dans la présente invention....
La présente invention concerne un procédé nouveau et amélioré de préparation du tétrapeptide H-Tyr-D-Ala-Phe(F)-Phe-NH2 qui est un peptide de formule (I). On décrit ce tétrapeptide ou un sel pharmaceutiquement acceptable de ce dernier ainsi que de nouveaux intermédiaires utiles dans la préparation dudit tét...
The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, h...
The present invention discloses a new and improved process for the preparation of the tetrapeptide H-Tyr-D-Ala-Phe(F)-Phe-NH2 that is a peptide of formula (I), or a pharmaceutically acceptable salt thereof, as well as new intermediates in the preparation thereof. The novel process is a fragment synthesis and suitable f...
Novel unnatural dipeptoids of α-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, colorectal tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents, antiulcer agents, antidepressant agents...
La présente invention concerne l'utilisation du composé peptidique His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe en tant qu'agent thérapeutique destiné à la prophylaxie et/ou au traitement du cancer, de maladies auto-immunes, de maladies fibreuses, de maladies inflammatoires, de maladies neurodégén...
The invention relates to isolated cytolytic T cells which recognize complexes of HLA-B35 molecules and the peptide defined by SEQ ID NO: 2, as well as methods for identifying HLA-B35 positive cells. The method involves contacting the cytolytic T cells to a sample, and determining activity of these cytolytic T cells....
The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, h...
A method for purifying tPA or a plasminogen activator having an active site resembling that of tPA from an impure solution thereof which comprises contacting the impure solution with a solid support having bound thereto a tripeptide of the formula: -X-Y-argininal, wherein X and Y are amino acids selected from the group...
A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0. Exa...
The invention relates to compounds and methods for inhibiting human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4 using peptide analogs of Arg-Pro-Pro-Gly-Phe that contain one or more amino acid substitutions. The invention also includes screening methods for identifying compounds that ...
La présente invention concerne l'utilisation du composé peptidique His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe en tant qu'agent thérapeutique destiné à la prophylaxie et/ou au traitement du cancer, de maladies auto-immunes, de maladies fibreuses, de maladies inflammatoires, de maladies neurodégén...
Novel unnatural dipeptoids of .alpha.-substituted Trp-Phe derivatives useful as agents in the treatment of obesity, hypersecre-tion of gastric acid in the gut, gastrin-dependent tumors, or as-antipsychotics are disclosed. Further the compounds are antianxie-ty agents and antiulcer agents and are agents useful for preve...
La présente invention concerne un procédé de traitement du cancer ou d'inhibition des métastases chez un sujet en réduisant le pH extracellulaire intratumoral. Le procédé comprend l'étape consistant à administrer au sujet une quantité thérapeutiquement efficace d'une solution tampon ayant un pKa ...
The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, h...
The present invention is related to a novel process for preparing N-acetyl-(L)-4-cyanophenylalanine by resolving the racemic compound N-acetyl-(D, L)-4-cyanophenylalanine ethyl ester, and a novel process to prepare a stereoisomer of Ac-(L)-pAph-Chg-PalMe(3)-NH2 by using the intermediate N-acetyl-(L)-4-cyanophenylalanin...
The invention comprises novel intermediates of the following general formula : (see formula I) These intermediates are suitable for the preparation of novel unnatural dipeptoids of a-substituted Trp-Phe derivatives which are useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut and gas...
Disclosed are DNA sequences encoding deletion, substitution and/or addition analogs of the E. coli enzyme, chorismate mutase/prephenate dehydratase (CMPD). Preferred expression products include [des-Gln³⁰⁷, des-Ala³⁰⁸, des-Gly³⁰⁹, des-Ala³¹⁰]CMPD; [Leu³⁰⁶]CMPD; [des-Thr³⁰⁴, Lys³⁰⁵, d...
本发明公开了氨基酸-(3,4-二羟基-Phe)-Ser-Leu伪肽及其合成方法和应用。其合成方法包括:(1)合成保护的(3,4-二羟基-Phe)-Ser-Leu;(2)将甘氨酸,丙氨酸,缬氨酸,亮氨酸,异亮氨酸,苯丙氨酸,酪氨酸,色氨酸,丝氨酸,苏氨酸,脯氨酸,谷氨酰...
La présente invention concerne un procédé nouveau de préparation de N-acétyl(L)-4-cyanophénylalanine par résolution du composé racémique N-acétyl-(D, L)-4-cyanophénylalanine éthyle ester et un procédé nouveau de préparation d'un stéréoisomère d'Ac-(L)-pAph-Chg-PalMe(3)-NH2 grâce à l'util...